Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome.

OBJECTIVES: Mutations affecting the TMEM173 gene cause STING-associated vasculopathy with onset in infancy (SAVI). No standard immunosuppressive treatment approach is able to control disease progression in patients with SAVI. We studied the efficacy and safety of targeting type I IFN signaling with the Janus kinase inhibitor, ruxolitinib.
METHODS: We used DNA sequencing to identify mutations in TMEM173 in patients with peripheral blood type I IFN signature. The JAK1/2 inhibitor ruxolitinib was administered on an off-label basis.
RESULTS: We identified three patients with SAVI presenting with skin involvement and progressive severe interstitial lung disease. Indirect echocardiographic signs of pulmonary hypertension were present in one case. Following treatment with ruxolitinib, we observed improvements of respiratory function including increased forced vital capacity in two patients, with discontinuation of oxygen therapy and resolution of echocardiographic abnormalities in one case. Efficacy was persistent in one patient and only transitory in the other two patients. Clinical control of skin complications was obtained, and one patient discontinued steroid treatment. One patient, who presented with kidney involvement, showed resolution of hematuria. One patient experienced increased recurrence of severe viral respiratory infections. Monitoring of peripheral blood type I interferon signature during ruxolitinib treatment did not show a stable decrease.
CONCLUSIONS: We conclude that targeting type I IFN receptor signaling may represent a promising therapeutic option for a subset of patients with SAVI syndrome and severe lung involvement. However, the occurrence of viral respiratory infection might represent an important cautionary note for the application of such form of treatment.

Introduction

Type I interferonopathies are a new class of disorders linked to the upregulation of type I interferon (IFN) [1, 2]. Stimulator of IFN genes (STING)-associated vasculopathy with onset in infancy (SAVI) is caused by gain of function mutations in TMEM173 [3], which lead to a constitutive production of high levels of type I IFNs without infectious triggers [3-5]. SAVI is characterized by systemic inflammation, chronic anemia, growth failure, cutaneous necrotic lesions, and interstitial lung disease [3, 6]. Low-titer autoantibodies (i.e., anti-nuclear antibody, anti-cardiolipin antibodies) can also be present. Therapeutic management is challenging: steroids are partially effective; patients respond poorly to disease-modifying therapies, such as methotrexate, mycophenolate mofetil, anti-malarials, infliximab, and rituximab [3, 6, 7]. Prognosis is poor especially in patients with a severe lung involvement, with a high mortality in the first two decades of life [3].

In light of the encouraging results obtained with the use of JAK inhibitors in other interferonopathies [8], and the ability of blocking type I IFN pathway activation in SAVI PBMC in vitro [3], a few SAVI patients have been treated with JAK1/2 inhibitors with good responses [9, 10].

We describe three SAVI patients with severe pulmonary involvement in which treatment with the JAK1/2 inhibitor, ruxolitinib, led to marked amelioration of disease manifestations that was sustained in one patient, but only transient in the other two.

Patients and Methods

The local ethics committees of Giannina Gaslini Institute and Ospedale Pediatrico Bambin Gesù approved the study.

IFN signature was performed as described [11] with minor modifications. Briefly, RNA was extracted from whole blood from peripheral venipuncture drawn in PAXgene tubes using PAXgene Blood RNA Kit (Qiagen, Hilden, Germany). cDNA was retrotranscribed using SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, California, USA). Selected IFN-stimulated gene (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1) expression was quantified by real-time PCR using gene-specific primers and probes (Roche) with the ddCt method relatively to a healthy donor calibrator using HPRT and G6PD as reference genes. In case samples were run in different assays, the same healthy donor calibrator was used and a positive control was added to assess inter-assay variability.

Mutations in the TMEM173 gene were assessed by standard Sanger sequencing (P1 and P2) or targeted resequencing using a customized panel and analyzed with the NextSeq sequencing platform (Illumina, San Diego, California, USA) (P3). Sequences are analyzed using a bioinformatics pipeline integrated in the BaseSpace Illumina System, and variants are called by VariantStudio Software. Variants identified by next-generation sequencing have been validated by Sanger sequencing.

The dyspnea score was defined as follows: 0: absence of dyspnea; 1: dyspnea only during intense physical activity, such as gymnastics at school; 2: dyspnea on moderate physical activity, such as climbing steps; 3: dyspnea walking; and 4: dyspnea at rest.

Results

Clinical Presentation

Patient 1 (current age 13 years old), born from healthy unrelated parents, presented at the age of eight months with isolated erythematosus-infiltrated skin lesions with pustular evolution followed by scarring, chilblains, and severe nail dystrophy by three years of age (Fig. 1a). Skin biopsy of an active nummular violaceous lesion and a scar resolution of a preexisting lesion revealed granulomatous nodular dermatitis, with deep granulomatous folliculitis and secondary fibrosis. The child presented recurrent episodes of bronchospasm, recurrent fever episodes, and worsening of skin lesions. At the age of eight years, focal thickening of the interlobular septa with areas of ground glass opacities with predominant sub-pleural distribution were evident at chest CT (Fig. 1a). A lung biopsy revealed lymphocytic aggregates in the peribronchial interstitial areas with aspects of capillaritis, and contiguous focal sub-atelectasis with macrophages infiltrating the alveoli (Table 1). Immunological studies revealed increased IgG and IgE, normal lymphocyte subset distribution, and normal lymphocyte proliferation in response to mitogens. Tetanus toxoid-specific IgG were below the protective level when tested at nine years of age (Table 2). Spirometry revealed mixed restrictive and obstructive features (Fig. 1a, Table 3). Differently from the cases described so far, mild renal involvement (microscopic hematuria, mild proteinuria, no biopsy was performed) was also present, associated with hypertension. Steroids (prednisone 1 mg/kg/day) ameliorated the clinical manifestations with normalization of inflammatory markers. However, disease relapses were observed during steroid tapering. Azathioprine and etanercept were ineffective. Peripheral blood type I IFN signature revealed the activation of type 1 IFN-induced gene expression (Supplementary Fig. 1A). Sanger sequencing of the TMEM173 gene identified a de novo c.463G>A p.Val155Met mutation [14].

Fig. 1

Clinical abnormalities in SAVI patients and response to JAK inhibitor therapy. Images of skin lesions in the three patients are shown in a, b, and c. CT scan showing interstitial lung disease and ground glass appearance in P1 (a) and dense patchy areas of ground glass opacity (probably correlated to previous pulmonary hemorrhages), which appear centrilobular and lobular mainly in the upper lobes in P3 (c). Pulmonary function test of P1 (a) and P2 (b) showing a mixed restrictive and obstructive alteration. Response to therapy is shown in the lower panels. Curves represent patients’ FVC, with L/s in the y-axis and L in the x-axis. Straight lines represent expected values by age. In P3 (c), diffuse multifocal regions of ground-glass opacity and cystic airspace in the left lower lobe (arrow) were present six months after therapy. PFT were not performed due to age. d H&E staining of punch skin biopsy from P3 showing parakeratosis and basal vacuolar degeneration of the epithelium and voluminous dermal interstitial and perivasal neutrophil inflammatory infiltrates without vasculitic damage of vessel walls at different magnifications. L liters, FVC forced vital capacity

Table 1

Patient characteristics

		Pat. 1	Pat. 2	Pat. 3
Mutation		V155M	R281Q	N154S
Mutation type		Heterozygous	Heterozygous	Heterozygous
Sex		F	F	F
Age (years)		10	8	2
Age onset		8 months	3 months	3 days
Failure to thrive		+	+	+
Recurrent fever		+	+	+
Severe infections before ruxolitinib therapy		–	Bronchiolitis, pneumonia (S. pneumoniae, P. aeruginosa), chronic lung colonization (P. aeruginosa)	–
Acute-phase reactants	CRP (mg/dl, n.v. < 0.46)	0–4.2	0–15	12–34
	ESR (mm/h, n.v. < 10)	48–57	23–24	20–79
Acral ulcers		++	+	++
Skin		Maculopapular lesions evolving to ulcers	Malar rash	Erythematosus vesicular rash on nose, cheeks, hands, and feet with evolution to pustules and scars
Histological findings at skin biopsy		Granulomatous nodular dermatitis, with deep granulomatous folliculitis and secondary fibrosis	Not performed	Neutrophilic dermatosis with karyorrhexis throughout the vessel wall
Interstitial lung disease		+	++	++
Histological findings at lung biopsy		Lymphocytic aggregates in the peribronchial interstitial areas with aspects of capillaritis, and contiguous focal sub-atelectasis with macrophages infiltrating the alveoli	Interstitial fibrosis without signs of vasculitis	Not performed
Auto antibodies		ANA, pANCA, PR3	cANCA, anti-cardiolipin, B2GLG	cANCA, PL, anti-cardiolipin, PT
Arthralgia or arthritis		+	–	–
Nephrology		Hypertension microhematuria	Hypertension	–
Ineffective drugs		AZA, etanercept	MTX, infliximab
Years at ruxolitinib start		9	7	2

ANA anti-nuclear antibodies, ANCA anti-neutrophil cytoplasm antibodies, PR3 anti-proteinase 3 antibodies, B2GLG anti-beta2 glycoprotein, IgG subtype, PL anti-phospholipid antibodies, PT anti-prothrombin antibodies, AZA azathioprine, MTX methotrexate

Table 2

Immunological parameters

		Pat. 1	Pat. 2	Pat. 3
Autoantibodies		ANA, pANCA, PR3	cANCA, anti-cardiolipin, B2GLG	cANCA, PL, anti-cardiolipin, PT
Age at immunoglobulins and lymphocyte subset analysis (years)		12	8	1 year and 10 months
Total immunoglobulins	IgA mg/dl	274 (n.v. 70–400)	340 (n.v. 34–305)	130 (n.v. 36–165)
	IgG mg/dl	1631 (n.v. 700–1600)	1639 (n.v. 500–1560)	1674 (n.v. 520–1400)
	IgM mg/dl	195.0 (n.v. 40–230)	138 (n.v. 25–210)	266 (n.v. 35–104)
	IgE (KU/l)	855 (n.v. < 200)	89,7 (n.v. < 90)	14,8 (n.v. < 40)
CD3 (a.n.)		1008 (n.v. 700–3200)	1039 (n.v. 700–3200)	2953 (n.v. 2100–6200)
CD4 (a.n.)		645 (n.v. 300–2000)	742 (n.v. 300–2400)	1988 (n.v. 1300–3400)
CD8 (a.n.)		337 (n.v. 300–1800)	313 (n.v. 300–1800)	812 (n.v. 620–2000)
CD19 (a.n.)		238 (n.v. 200–1600)	208 (n.v. 100–1200)	1647 (n.v. 720–2600)
CD3-CD56+ (a.n.)		54 (n.v. 90–900)	346 (n.v. 90–1000)	994 (n.v. 180–920)
CD4 CD45RA+ (% of CD4+)		73 (n.v. 46–77)	92 (n.v. 46–77)	85 (n.v. 63–91)
CD4 CD45RO+ (% of CD4+)		27 (n.v. 13–30)	8 (n.v. 13–30)	15 (n.v. 7–20)
CD8 CD45RA+ (% of CD8+)		NA	93 (n.v. 63–92)	70 (n.v. 71–98)
CD8 CD45RO+ (% of CD8+)		NA	7	30
Lymphocyte proliferation		Normal in response to PHA	Normal in response to PHA	Normal in response to PHA, defective to OKT3
Vaccinations		DtP, Polio, Hib, hepatitis B, MMR (1 dose)	DtP, Polio, Hib, hepatitis B, MMR	Not performed
Response to vaccine (years of age when tested)		Nonprotective to tetanus toxoid and diphtheria (9)	Protective to tetanus toxoid (8)	Not tested

Numbers in italics means abnormal for age-specific reference ranges[12, 13]

DtP diphtheria, tetanus toxoid, and pertussis, Hib Haemophilus influenzae type B, MMR measles, mumps, and rubella, PHA phytohemagglutinin

Table 3

Response to therapy

Time point (months)		0	3	6	10	12	18	23	32
Ruxolitinib, mg/day (mg/kg/day)	P1	0	10 (0.3)	15 (0.5)		20 (0.6)	20 (0.6)	20 (0.6)	20 (0.6)
	P2	0	5 (0.25)	10 (0.5)		15 (0.7)	5 (0.2)
	P3	0	5 (0.45)	15 (1.3)
Weight, kg (centile)	P1	24 (5–10)	29 (10–25)	29 (10–25)		30 (10–25)	32 (10–25)	32 (5–10)	33 (5–10)
	P2	20 (3–5)	21 (10–25)	20.4 (3–5)		21.5 (10–25)	24.6 (10–25)	26 (10–25)
	P3	10 (3–10)	NA	11.8 (3–25)
Height (centile)	P1	< 3	< 3	< 3		< 3	< 3	< 3	< 3
	P2	< 3	< 3	< 3		< 3	< 3	< 3
	P3	3–10	NA	25–50
FVC	P1	1.1	1.2	1.3		1.4	1.3	1.6	1.5
	P2	0.3	0.6	0.7		NP	NP
FVC %	P1	70	84	82		87	90	96
	P2	40	54	53		NP	NP
Sat. O2% 6MWT	P1	----------------------------------------------------NP--------------------------------------------------------
	P2	84 *	90	98		NP	NP
Dyspnea	P1	3.0	0.5	0.5		0.5	0.5	0.5	0
	P2	4	1	1		2	3
Prednisone (mg/kg/day)	P1	0.4	0.2	0.2		0.1	0.1	0.1	0
	P2	0.3	0.3	0.2
	P3	0	0	0	2**
CRP (mg/dl) n.v. < 0.4	P1	3.6	0	0.99		0	0	0	NP
	P2	0.48	0.49	1.74		0	0
	P3	2.66	0.89	0.83	2.28
ESR (mm/h) n.v. < 10	P1	55	43	20		35	30	NP	NP
	P2	26	32	39		24	23
	P3	76	36	40	79
Hb (mg/dl)	P1	6.7	13.2	13.5		12.4	12	11.7	10.6
	P2	12.6	13	12.9		13.2	14.2
	P3	7	8.3	9.4
Neutrophils (a.n./μl)	P1	6090	3380	4250		2160	2190	3490	3100
	P2	7.23	7.98	7.01		6.98	9.220	3.87
	P3	6720	4520	5570	5800
Lymphocytes (a.n./μl)	P1	2450	1780	1340		1320	1720	730	960
	P2	900	1470	1040	1670	1830	820	2200
	P3	4530	3510	1220
Platelets (103/μl)	P1	473	441	383		409	305	355	387
	P2	465	487	478	816	414	440	461
	P3	716	649	766

Numbers in italics means abnormal according to age-specific reference ranges

*Interrupted after 4 min for respiratory distress. P3 did not perform respiratory function tests due to his young age

**Restarted oral prednisone at 2 mg/kg/day at 10 months because of worsening of the radiological signs of disease at chest CT

NP did not perform, 6MWT 6 min walking test, FVC forced vital capacity, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hb hemoglobin

Patient 2 (current age ten years old) was recently described [15]. She presented at the age of three months with growth failure and respiratory distress (Table 1). Livedo reticularis was present on the lower limbs (Fig. 1b). The patient required several ICU admissions for ventilator support during lower airway infections (bronchiolitis and pneumonia). CT scan showed extensive ground glass abnormalities (Fig. 1b). Chronic Pseudomonas aeruginosa infection was documented. Lung biopsy showed interstitial fibrosis without signs of vasculitis. Echocardiographic imaging showed indirect signs of pulmonary hypertension and mild dilation of the pulmonary artery. Steroids were only partially effective, and association of methotrexate and infliximab were ineffective, resulting in steroid dependency. Daily oxygen support and non-invasive ventilation at night were required. Cheeks and nose telangiectatic skin lesions and unilateral vocal cord paresis were also observed (Fig. 1b, Table 1 and Table 3). Except for the elevation of total IgA and IgG and a mild lymphopenia, immunological studies did not reveal major alterations (Tables 2 and 3). Peripheral blood type I IFN signature was positive (Supplementary Fig. 1A). Targeted sequencing revealed a c.842G>A p.Arg281Gln mutation in TMEM173 [15].

Patient 3 (current age three years old), the only child of healthy, unrelated parents, presented at three days of life, with an erythematosus vesicular rash on the nose and cheeks, later spreading to her hands and feet with evolution to pustules and scars (Fig. 1c and Table 1). She was admitted at the age of three months with recurrent low-grade fever, cough, diarrhea, and dermatitis variably responsive to glucocorticoids and antibiotics in the suspect of a combined immunodeficiency. Skin biopsy was consistent with neutrophilic dermatosis with karyorrhexis throughout the vessel wall (Fig. 1d). Chest CT revealed focal thickening of the interlobular septa with areas of ground glass opacities. Blood investigations revealed microcytic anemia, increased acute-phase reactants, hypergammaglobulinemia, mild reduction of C3 levels, and low-titer autoantibodies (anti-cardiolipin), with a normal distribution of lymphocyte subsets. Lymphocyte proliferation was normal in response to PHA and low but present in response to OKT3 (Tables 1 and 2). Peripheral blood type I IFN signature was positive (Supplementary Fig. 1A). The patient was started on glucocorticoids (1 mg/kg/day prednisone) with improvement of clinical and laboratory findings, but recurrence of symptoms at tapering. Targeted genome sequencing revealed a de novo heterozygous mutation in TMEM173 c.461A>G (p.Asn154Ser).

Ruxolitinib Therapy Efficacy, Limits, and Side Effects

Treatment with ruxolitinib was started initially at 0.25 mg/kg/day in two doses, and subsequently progressively increased until clinical efficacy was obtained, namely, to 0.65 mg/kg/day in P1, 0.7 mg/kg/day in P2, and 1.25 mg/kg/day in P3.

All patients showed an initial clinical response starting in the first weeks of treatment and evident after three months (Figs. 1 a and 2 a, Table 3), with amelioration of lung disease (assessed by pulmonary functional tests and CT scans) and resolution of cutaneous lesions that was stable in P1 and only transient in P2 and P3. Furthermore, P1 showed resolution of the microhematuria and was able to progressively taper steroids and stop them after two years.

Fig. 2

Response to JAK inhibitor treatment and side effects. Steroid dose and lung disease evolution in response to ruxolitinib therapy (a). Relative quantification of gene expression of six interferon-stimulated genes at baseline and after ruxolitinib treatment; “m + number” indicates months of therapy (b). Infection occurrence in P2 (c). HD healthy donors, FVC forced vital capacity

P2 also showed amelioration of the skin phenotype, reduction of the dyspnea that correlated with an improvement in the 6-min walking test (O2 saturation at the end of the test improved from 84 to 98%), and increase in total forced vital capacity (Figs. 1 b and 2 b, Table 3). Furthermore, echocardiographic improvement of the indirect signs of pulmonary hypertension was documented, with normalization of pulmonary artery size.

P3 initially showed a good clinical response with amelioration of skin lesions and radiological lung findings (Fig. 1c, Table 3).

Notably, the clinical responses did not correlate with decreased type I IFN signatures, which improved only transiently in P1 during concomitant treatment with high dose steroids and ruxolitinib (Fig. 2b).

During three years of ruxolitinib treatment, P1 presented three flares of the skin lesions requiring brief cycles of steroids. No severe infections occurred. BK virus in the urines was intermittently detected (viral copies from thousands to 2 million/ml), without BK viremia, nor alteration of kidney function.

P2 (follow-up of 18 months) starting from seven months of therapy, experienced an increase in hospitalization because of respiratory infections, caused by Pseudomonas aeruginosa exacerbation, several episodes of rhinovirus infection, influenza A, varicella, and coronavirus (the last requiring mechanical ventilation and extracorporeal membrane oxygenation for 11 days), prompting the decision of reducing ruxolitinib dosage (Fig. 2c). At 18 months of therapy, CT scan revealed a worsening of the interstitial disease with a ground glass appearance and interlobular thickening (Fig. 1b).

P3 (follow-up of 12 months) after ten months on treatment on ruxolitinib presented clinical and radiological relapse of lung disease requiring glucocorticoid therapy (2 mg/kg/day of prednisone) with a prompt response (Fig. 2a). She never presented viral or bacterial infections since the beginning of therapy. Cell blood counts and ruxolitinib serum levels were regularly monitored (Supplementary Fig. 1B, Supplementary Table 1). No cytopenia was observed during the follow-up (Table 3). All patients are continuing ruxolitinib treatment at the time of writing.

Discussion

Our report confirms that JAK inhibition is a therapeutic resource worth considering for patients with SAVI, including very young children, as in the case of P3, also taking into account that the disease poorly responds to any other available immune-modifying agents. However, contrary to published reports, we observed several episodes of severe viral infections in one patient, suggesting the possibility that JAK inhibitors might significantly increase the risk of infections possibly in cases of more severe lung involvement or in the presence of genetic modifiers, not investigated in our patient, with consequent deterioration of the lung disease. Interestingly, the most frequent virus isolated was rhinovirus, which may be a direct consequence of effective type I IFN inhibition by ruxolitinib at least in respiratory epithelial cells, where IFN-β is required to control rhinovirus [16, 17]. On the other end, these infections might result from a cumulative effect of the drug with the reported developmental and in vitro proliferative defects of STING mutant T lymphocytes [18, 19]. Considering the severity of lung disease and the lymphopenia (Table 2) present before ruxolitinib treatment, P2 was started on antibiotic prophylaxis with Bactrim and Azithromycin; that, however, did not seem to prevent the febrile episodes, mostly if not always caused by viral pathogens. Of note, the patient is now on IVIG prophylaxis and no severe infections have been reported so far. Whether this is due to ruxolitinib reduction and/or IVIG treatment, it is difficult to understand.

We observed a variable medium- and long-term clinical response to the therapy. Only P1 seemed to reach a stable control of the disease, while P2 and P3 required at some point the introduction (P3) or the increase (P2) in steroids to control flares. Several factors might have played a role, including variability of disease severity and inadequate plasma drug levels. Indeed, while all patients were steroid dependent and required several hospital admissions to treat flares, P2 and P3 appear to have a more severe phenotype, with P2 presenting several life-threatening exacerbations requiring admission to ICU and ventilator support during infection episodes and P3 presenting a very early disease onset (three days of life). Additionally, despite dose adjustment and plasma level monitoring, drug dosage appeared to be stably adequate only in P1 (Supplementary Fig. 1 and Supplementary Table 1). Notably, we reduced ruxolitinib dosage in P2 after one year of therapy, in the attempt to prevent infections (Fig. 1c).

Overexpression of a set of interferon-stimulated genes (ISGs) in peripheral blood has consistently been found in all reported patients with SAVI syndrome [6, 14, 15]. Modulation of IFN signature following treatment may represent a surrogate biomarker. However, we did not observe a consistent decrease in IFN signature during the treatment. In previous reports of ruxolitinib treatment in patients with SAVI [9, 10, 20], only a partial or no decrease in IFN signature was observed. The lack of downregulation of IFN signature might be explained by the fast kinetic of JAK inhibition by ruxolitinib as shown by the transient decrease in pSTAT1 following drug intake [9] which seems not to be coupled with a clear impact on ISG expression (Supplementary Fig. 2). Otherwise, it might suggest that the six gene–based test is not appropriate to assess type I interferon activation at least in patients with SAVI treated with a JAK inhibitor.

Finally, it is important to consider that ruxolitinib inhibits not only the signaling of type I interferon receptor but also that of other receptors involved in important inflammatory pathways such as IL6, IL12/23, and interferon γ. It is possible that the inhibition of some or all of these pathways is responsible for the therapeutic efficacy (and side effects) we see in SAVI.

In conclusion, SAVI disease still appears to be orphan of ideal therapeutic targets. Despite the encouraging results obtained in this and previous reports [9, 10], prospective studies with a greater number of patients are warranted to address all the crucial issues linked to JAK inhibitor use in patients with SAVI.

(DOCX 16 kb)

(PDF 180 kb)

(PDF 100 kb)